DCC-2036

DCC-2036 (Rebastinib) is a highly potent, non-ATP-competitive BCR-ABL1 inhibitor with IC50 of 0.8 and 4 nM for native ABL1 and gatekeeper mutant ABL1 T315I, respectively.

Target : Bcr-Abl

CAS Number : 1020172-07-9

Formula Weight : 553.5869

Molecular Formula : C30H28FN7O3

Purity : >98% (HPLC)

Storage : (-20?)

Shipping Conditions : With Ice Pack

Stability : ? 2 years

Research use only, not for human use.